SAN CARLOS, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present and participate in the following conferences in November:
- Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018.
- Jefferies Global Healthcare Conferencein London, United Kingdom on Thursday, November 15, 2018 at 4:00 p.m. GMT.
- Evercore ISI HealthCONx Conferencein Boston, MA on Tuesday, November 27, 2018 at 11:20 a.m. ET.
A live audio webcast of the Jefferies and Evercore ISI conference presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using TIL technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
John Capodanno
FTI Consulting
212-850-5705
john.capodanno@fticonsulting.com
Iovance Biotherapeutics, Inc.
